Report cover image

Methicillin-resistant Staphylococcus Aureus Drugs Market - By Drug Class (Glycopeptides), MRSA Type (Hospital-acquired, Community-acquired), Route of Administration, Indication (Bacteraemia), Distribution Channel - Global Forecast (2024 - 2032)

Publisher Global Market Insights
Published Apr 30, 2024
Length 190 Pages
SKU # GMI19023966

Description

Methicillin-resistant Staphylococcus Aureus Drugs Market - By Drug Class (Glycopeptides), MRSA Type (Hospital-acquired, Community-acquired), Route of Administration, Indication (Bacteraemia), Distribution Channel - Global Forecast (2024 - 2032)
Global Methicillin-resistant Staphylococcus Aureus Drugs Market size will witness 4.2% CAGR between 2024 and 2032 owing to ongoing challenges, triggered by antibiotic-induced Staphylococcus aureus strains. Conventional antibiotics against methicillin-resistant staphylococcus aureus MRSA are ineffective, and new treatment options are critically needed.

Pharmaceutical companies, research institutes, and government agencies are also intensifying their efforts to develop new drugs, vaccines, and therapeutic strategies to combat MRSA infections. For instance, in December 2023, scientists discovered a new class of antibiotics for drug-resistant Staphylococcus aureus bacteria from the utilization of more transparent deep learning models. Advances in genomics, immunology, and drug discovery mechanisms are also providing new insights into the pathogenesis of MRSA infections and potential therapeutic targets for emphasizing the importance of emergency medicine. This increased focus on RampD is poised to drive innovations and shape the future of MRSA treatments.

The overall industry is classified into drug class, MRSA type, route of administration, indication, distribution channel and region.

According to drug class, the methicillin-resistant staphylococcus aureus drugs industry from the lipopeptides segment will undergo rigorous development from 2024 to 2032. Lipopeptides are promising antimicrobial agents, known for their potent activity against MRSA and other drug-resistant bacteria. As MRSA strains are poorly responsive to conventional antibiotics, lipopeptides offer valuable alternatives due to their unique mechanism of action and low resistance. Several pharmaceutical companies are also focusing on developing and marketing lipopeptide-based drugs to combat the growing threat of MRSA infections.

On the basis of MRSA type, the methicillin-resistant staphylococcus aureus drugs market from the community acquired CA-MRSA segment will register notable CAGR from 2024 to 2032. This is due to the rise in CA-MRSA infections, which pose a serious public health concern. The ability of CA-MRSA strains to cause serious infections in otherwise healthy individuals, has led to the increasing demand for effective treatment. Pharmaceutical companies are also focusing on drugs targeting CA-MRSA strains to combat this growing threat.

Europe methicillin-resistant staphylococcus aureus drugs market will showcase a commendable CAGR from 2024 to 2032 due to the increasing need for effective treatments. With the increasing incidence of healthcare-associated and community-acquired MRSA infections, new antibiotics are urgently required in the region. Pharmaceutical companies are also investing in RampD activities to meet this demand while introducing new drugs to combat the prevalence of MRSA strains in Europe.

Table of Contents

190 Pages
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of MRSA infections
3.2.1.2 Growing antibiotic resistance
3.2.1.3 Advancements in drug development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of therapeutics
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)
5.1 Key trends
5.2 Glycopeptides
5.3 Lipopeptides
5.4 Oxazolidinones
5.5 Cephalosporin
5.6 Tetracycline
5.7 Folate antagonist
5.8 Other drug classes
Chapter 6 Market Estimates and Forecast, By MRSA Type, 2021 - 2032 ($ Mn)
6.1 Key trends
6.2 Hospital-acquired (HA-MRSA)
6.3 Community-acquired (CA-MRSA)
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)
8.1 Key trends
8.2 Skin and soft tissue infections
8.3 Bone & joint infections
8.4 Respiratory infections
8.5 Bacteremia
8.6 Other indications
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 AbbVie Inc.
11.2 Basilea Pharmaceutica Ltd
11.3 Baxter International Inc.
11.4 Cumberland Pharmaceuticals Inc.
11.5 GlaxoSmithKline plc.
11.6 Johnson & Johnson
11.7 Merck & Co., Inc.
11.8 Novartis AG
11.9 Pfizer Inc.
11.10 Teva Pharmaceutical Industries Ltd.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us